Castle Biosciences (CSTL) to Release Earnings on Thursday

Castle Biosciences (NASDAQ:CSTL) is expected to be releasing its earnings data after the market closes on Thursday, February 27th. Analysts expect Castle Biosciences to post earnings of ($0.04) per share and revenue of $83.89 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Castle Biosciences Trading Down 1.1 %

CSTL stock opened at $25.09 on Wednesday. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. Castle Biosciences has a 12-month low of $16.97 and a 12-month high of $35.84. The stock has a market cap of $702.70 million, a price-to-earnings ratio of 125.46 and a beta of 0.91. The business’s 50-day moving average is $27.40 and its 200 day moving average is $29.24.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CSTL. Stephens reaffirmed an “overweight” rating and set a $41.00 price target on shares of Castle Biosciences in a research report on Thursday, January 2nd. KeyCorp boosted their price target on shares of Castle Biosciences from $28.00 to $36.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Scotiabank boosted their target price on shares of Castle Biosciences from $37.00 to $44.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, November 6th. Canaccord Genuity Group boosted their price target on shares of Castle Biosciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, October 29th. Finally, Robert W. Baird upped their target price on shares of Castle Biosciences from $37.00 to $39.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $40.29.

Insider Activity at Castle Biosciences

In other news, insider Derek J. Maetzold sold 9,364 shares of Castle Biosciences stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $28.34, for a total value of $265,375.76. Following the completion of the transaction, the insider now directly owns 84,762 shares of the company’s stock, valued at approximately $2,402,155.08. The trade was a 9.95 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Daniel Bradbury sold 7,867 shares of Castle Biosciences stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total transaction of $221,613.39. The disclosure for this sale can be found here. In the last three months, insiders sold 30,771 shares of company stock valued at $886,112. Corporate insiders own 7.20% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.